Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company focused on developing novel cell and gene immunotherapies. These therapies are designed to treat a range of conditions including cancer, autoimmune diseases, and respiratory diseases. Founded in 2016, the company operates in the biotechnology sector and serves patients who are in need of advanced therapeutic options. Cartesian Therapeutics combines discovery, cGMP manufacturing, and clinical operations under one roof, ensuring a streamlined process from research to patient care. The business model revolves around the development and clinical testing of its proprietary therapies, which are then licensed or sold to larger pharmaceutical companies. Revenue is generated through these partnerships, as well as through grants and research funding. The company is currently engaged in multiple active clinical trials aimed at validating the efficacy and safety of its treatments.

Keywords: cell therapy, gene therapy, cancer treatment, autoimmune diseases, respiratory diseases, biopharmaceutical, clinical trials, cGMP manufacturing, immunotherapy, biotechnology.